NHS Logo
Image from Google Jackets

The clozapine handbook : Stahl's handbooks

By: Contributor(s): Series: Stahl's Essential Psychopharmacology Handbooks | Cambridge medicinePublication details: Cambridge : Cambridge University Press, 2019.Description: xi, 317pISBN:
  • 9781108447461
Subject(s): NLM classification:
  • WM 402.
Contents:
Preface 1. Initiating Clozapine 2. Understanding hematologic monitoring and benign ethnic neutropenia 3. Binding profile, metabolism, kinetics, drug interactions and use of plasma levels 4. Managing constipation 5. Managing sialorrhea 6. Managing sedation, orthostasis and tachycardia 7. Managing metabolic adverse effects 8. Managing seizure risk and stuttering 9. Fever, myocarditis, interstitial nephritis, DRESS, serositis and cardiomyopathy 10. Eosinophilia, leukocytosis, thrombocytopenia, thrombocytosis, anemia, hepatic function abnormalities 11. Managing enuresis and incontinence, priapism, venous thromboembolism, neuroleptic malignant syndrome, tardive dyskinesia and obsessive compulsive disorder 12. The efficacy story: treatment resistant schizophrenia, psychogenic polydipsia, treatment intolerant schizophrenia, suicidality, violence, mania and Parkinson's disease psychosis 13. Addressing clozapine positive symptom nonresponse in schizophrenia spectrum patients 14. Discontinuing clozapine and management of cholinergic rebound 15. Special topics: child and adolescent patients, elderly patients, patients with intellectual disability, pregnancy and risk for major congenital malformation, lactation, overdose, postmortem redistribution Index.
Summary: Real-world and clinical trial data support that clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses. Clozapine also reduces rates of suicidality, psychiatric hospitalization and all-cause mortality. However, clozapine is underutilized for two reasons: misunderstandings of its efficacy benefits and misapprehension of, limited knowledge or misinformation about the management of treatment related risks and adverse effects. In response to worldwide efforts to promote clozapine use, this user-friendly Handbook provides clinicians with evidence-based approaches for patient management, as well as logical approaches to the management of clinical situations and adverse effects. It outlines clearly the rationale for specific management decisions and prioritises the options based on this logic. This Handbook is designed for use by clinicians worldwide and is essential reading for all mental health care professionals.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Home library Class number Status Date due Barcode
Book Oxleas NHS Foundation Trust Knowledge and Library Service Library Office WM 402 MEY (Browse shelf(Opens below)) Available x02081
Book Oxleas NHS Foundation Trust Knowledge and Library Service Library Office WM 402 MEY (Browse shelf(Opens below)) Available x02083
Book Oxleas NHS Foundation Trust Knowledge and Library Service Library Office WM 402 MEY (Browse shelf(Opens below)) Available x02082
Book South London and Maudsley Trust Library Shelves WM 402 MEY (Browse shelf(Opens below)) Available 023415
Book South London and Maudsley Trust Library Shelves WM 402 MEY (Browse shelf(Opens below)) Available 023390

Copyright date is 2020 but actually published in 2019.

Preface
1. Initiating Clozapine
2. Understanding hematologic monitoring and benign ethnic neutropenia
3. Binding profile, metabolism, kinetics, drug interactions and use of plasma levels
4. Managing constipation
5. Managing sialorrhea
6. Managing sedation, orthostasis and tachycardia
7. Managing metabolic adverse effects
8. Managing seizure risk and stuttering
9. Fever, myocarditis, interstitial nephritis, DRESS, serositis and cardiomyopathy
10. Eosinophilia, leukocytosis, thrombocytopenia, thrombocytosis, anemia, hepatic function abnormalities
11. Managing enuresis and incontinence, priapism, venous thromboembolism, neuroleptic malignant syndrome, tardive dyskinesia and obsessive compulsive disorder
12. The efficacy story: treatment resistant schizophrenia, psychogenic polydipsia, treatment intolerant schizophrenia, suicidality, violence, mania and Parkinson's disease psychosis
13. Addressing clozapine positive symptom nonresponse in schizophrenia spectrum patients
14. Discontinuing clozapine and management of cholinergic rebound
15. Special topics: child and adolescent patients, elderly patients, patients with intellectual disability, pregnancy and risk for major congenital malformation, lactation, overdose, postmortem redistribution
Index.

Real-world and clinical trial data support that clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses. Clozapine also reduces rates of suicidality, psychiatric hospitalization and all-cause mortality. However, clozapine is underutilized for two reasons: misunderstandings of its efficacy benefits and misapprehension of, limited knowledge or misinformation about the management of treatment related risks and adverse effects. In response to worldwide efforts to promote clozapine use, this user-friendly Handbook provides clinicians with evidence-based approaches for patient management, as well as logical approaches to the management of clinical situations and adverse effects. It outlines clearly the rationale for specific management decisions and prioritises the options based on this logic. This Handbook is designed for use by clinicians worldwide and is essential reading for all mental health care professionals.

There are no comments on this title.

to post a comment.
London Health Libraries Consortium Privacy notice and Membership terms and conditions